FDA hits Ca­mu­rus with CRL for acromegaly ther­a­py over man­u­fac­tur­ing is­sues 

The FDA hand­ed a CRL to the Swedish biotech Ca­mu­rus for its hor­mone dis­or­der ther­a­py over “fa­cil­i­ty-re­lat­ed de­fi­cien­cies” at a third-par­ty man­u­fac­tur­er.

The ther­a­py, dubbed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER